Sign in

SPPI on NASDAQ

Spectrum Pharmaceuticals

Logo: Spectrum Pharmaceuticals, Public domain, via Wikimedia Commons5

American biopharmaceutical company

Spectrum Pharmaceuticals, Inc. is an American biopharmaceutical company located in Boston, MA. It develops and markets drugs for treatments in hematology and oncology. After a deal valued at $248 million was announced in April 2023, Assertio Holdings announced that it had completed its acquisition of the Massachusetts-based company on July 31.3 Its shares trade on NASDAQ under the symbol SPPI.1 Wikipedia text CC BY-SA 4.0

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with Janux Therapeutics, Inc., Zenas BioPharma, Inc. or PROTHENA CORP PUBLIC LTD CO, or pick any stock.

  • TickerSPPI on NASDAQ1
  • Industrypharmaceutical industry1
  • HeadquartersHenderson1
  • Websitewww.spectrumpharm.com
  • Legal formDelaware corporation1
  • Incorporated inDE6
  • Business address11500 S. Eastern Ave., Suite 240, Henderson, Nv 890526
  • Filer categoryNon-accelerated filer, Smaller reporting company6
  • LEI549300COU30WSP3O5I074
  • StatusActive4
  • LEI statusLapsed (not renewed)4
  • Registered addressC/O NATIONAL REGISTERED AGENTS, INC., 19801 Wilmington, United States4
  • Registered withDivision of Corporations, Department of State, 35924394

See how the biggest companies compare on our leaderboards

Spectrum Pharmaceuticals, Inc. is an American biopharmaceutical company located in Boston, MA. It develops and markets drugs for treatments in hematology and oncology.3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2022

-718.8%Operating margin8
-745.5%Net margin8
-270.4%Return on equity8
1.03×Debt to equity8
-$97.3MFree cash flow8

Where the money goes

Where each dollar of revenue went, fiscal 2022

  • Research and development52¢$42.2M
  • Selling, general and admin48¢$38.8M
  • Income tax0¢$46.0K

Out of $10.1M in revenue.8 The company lost money this year.

Financial statements

Revenue910118$10.1M in 2022−93% since 2016
0$50.0M$100.0M$150.0M2016: $146.4M$146.4M20162017: $0$020172018: $0$020182019: $0$020192020: $0$020202021: $0$020212022: $10.1M$10.1M2022
Operating income121011138-$72.7M in 2022+16% since 2016
-$200.0M-$150.0M-$100.0M-$50.0M02016: -$62.9M-$62.9M20162017: -$116.3M-$116.3M2017+85%2018: -$137.8M-$137.8M2018+19%2019: -$140.7M-$140.7M2019+2%2020: -$169.7M-$169.7M2020+21%2021: -$147.7M-$147.7M2021−13%2022: -$72.7M-$72.7M2022−51%
Net income121011138-$75.4M in 2022+8% since 2016
-$200.0M-$150.0M-$100.0M-$50.0M02016: -$69.8M-$69.8M20162017: -$92.2M-$92.2M2017+32%2018: -$120.7M-$120.7M2018+31%2019: -$112.7M-$112.7M2019−7%2020: -$160.9M-$160.9M2020+43%2021: -$158.6M-$158.6M2021−1%2022: -$75.4M-$75.4M2022−52%
Fiscal year2016201720182019202020212022
Revenue$146.4M9$010$010$011$011$08$10.1M8
Research and development$59.1M12$51.5M10$75.2M10$79.3M11$109.4M13$87.3M8$42.2M8
Selling, general and admin$88.4M12$64.8M10$62.7M10$61.4M11$60.4M13$60.4M8$38.8M8
Operating expenses$147.7M8$82.8M8
Operating income-$62.9M12-$116.3M10-$137.8M10-$140.7M11-$169.7M13-$147.7M8-$72.7M8
Interest$9.7M12$8.1M12$3.1M12
Income before tax-$158.4M8-$78.1M8
Income tax-$2.3M12-$21.9M10-$1.9M10-$9.2M11-$60.0K13$4.0K8$46.0K8
Net income-$69.8M12-$92.2M10-$120.7M10-$112.7M11-$160.9M13-$158.6M8-$75.4M8
Earnings per share-$0.9612-$1.0712-$1.1612-$1.2913-$1.028-$0.418
Earnings per share (diluted)-$0.9612-$1.0712-$1.1612-$1.2913-$1.028-$0.418
Shares (weighted, basic)154.9M shares8183.2M shares8
Shares (weighted, diluted)154.9M shares8183.2M shares8

Compare Spectrum Pharmaceuticals with another company

Corporate structure

Spectrum Pharmaceuticals is part of a group headed by Assertio Holdings, Inc.. 14 entities, 2 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Spectrum Pharmaceuticals

  • ARMISTICE CAPITAL, LLC Filed SC 13G/A on Spectrum Pharmaceuticals, latest Feb 14, 2023 (2 filings since Feb 15, 2022)
  • VANGUARD GROUP INC Filed SC 13G/A on Spectrum Pharmaceuticals, latest Feb 9, 2023 (2 filings since Feb 10, 2022)
  • BlackRock Filed SC 13G on Spectrum Pharmaceuticals, latest Jul 8, 2022 (4 filings since Jan 25, 2022)
  • MILLENNIUM MANAGEMENT LLC Filed SC 13G on Spectrum Pharmaceuticals, latest Feb 10, 2022
  • Hanmi Pharmaceutical Filed SC 13D on Spectrum Pharmaceuticals, latest Feb 1, 2022
  • State Street Corporation Filed SC 13G/A on Spectrum Pharmaceuticals, latest Jan 10, 2022 (2 filings since Oct 12, 2021)
  • Assertio Holdings, Inc. Lake Forest, Illinois
    • Spectrum Pharmaceuticals Henderson, Nevada, United States
    • Alligator IP, LLC Subsidiary · Delaware, United States
    • Allos Therapeutics, Inc. Subsidiary · Delaware, United States
    • ASIO Holdings, LLC Subsidiary · Texas, United States
    • Assertio Distribution, LLC Subsidiary · Delaware, United States
    • Assertio Management, LLC Subsidiary · Delaware, United States
    • Assertio Specialty Pharmaceuticals, LLC Subsidiary · Delaware, United States
    • Depo DR Sub, LLC Subsidiary · Delaware, United States
    • Spectrum Oncology Private Limited Subsidiary · India
    • Spectrum Pharmaceuticals International Holdings, LLC Subsidiary · Delaware, United States
    • Talon Therapeutics, Inc. Subsidiary · Delaware, United States
    • Zyla Life Sciences US, LLC Subsidiary · Delaware, United States
    • Zyla Life Sciences, LLC Subsidiary · Delaware, United States

Built from subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Spectrum Pharmaceuticals reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$3.4M13 Dec 31, 2021$6.4M13 Dec 31, 2020−47.2%
Accumulated depreciation$2.9M13 Dec 31, 2021$2.9M13 Dec 31, 2020+2.8%
Property and equipment, net$476.0K8 Dec 31, 2022$455.0K8 Dec 31, 2021+4.6%
Operating-lease assets (leased space)$1.7M8 Dec 31, 2022$2.5M8 Dec 31, 2021−32.4%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$40.4M8 Dec 31, 2022$88.5M8 Dec 31, 2021−54.4%
Marketable securities, current$34.7M8 Dec 31, 2022$12.1M8 Dec 31, 2021+186.8%
Equity securities at fair value$136.0K8 Dec 31, 2022$5.7M8 Dec 31, 2021−97.6%

Inventory

ItemLatestA year beforeChange
Inventory, total$9.2M8 Dec 31, 2022$08 Dec 31, 2021
Raw materials$4.5M8 Dec 31, 2022$08 Dec 31, 2021
Work in process$4.0M8 Dec 31, 2022$08 Dec 31, 2021
Finished goods$723.0K8 Dec 31, 2022$08 Dec 31, 2021

Leadership

Who has led Spectrum Pharmaceuticals, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Rajesh C. Shrotriya Md.2006–2017
  2. Joseph W. Turgeon2018–2021
  3. Thomas J. Riga2022–2023

Chair

  1. Rajesh C. Shrotriya Md.2006–2017

President

  1. Rajesh C. Shrotriya Md.2006–2014
  2. Joseph W. Turgeon2014–2021
  3. Thomas J. Riga2022–2023

Chief financial officer

  1. Brett L. Scott2010–2012
  2. Kurt A. Gustafson2013–2022
  3. Nora Brennan2022–2023

Chief operating officer

  1. Joseph Kenneth Keller2012–2013
  2. Joseph W. Turgeon2014–2017
  3. Thomas J. Riga2017–2021
2010201520202025
Board members and other officers (32)

Products and brands

Poziotinib is a tyrosine kinase inhibitor in development for use in patients with previously treated locally advanced or metastatic non-small cell lung cancer (NSCLC) with HER2 exon 20 insertion mutations.

Nov 28, 2022

Spectrum announced the lay off 75% of R&D staff after FDA New Drug Application (NDA) rejection. Spectrum also announced plans to discontinue development of poziotinib, and to explore “strategic alternatives” for the Poziotinib program.

Nov 25, 2022

Read the full text

Spectrum received a Complete Response Letter from FDA for Poziotinib.

Sep 22, 2022

Spectrum provided an update on Poziotinib following the FDA Oncologic Drugs Advisory Committee (ODAC) Meeting regarding Spectrum's New Drug Application (NDA).

The ODAC voted 9–4 against a Poziotinib approval as the advisers judged the drug's risks outweighed its benefits.

Feb 11, 2022

Spectrum announced FDA acceptance of the New Drug Application (NDA) submitted for Poziotinib

Dec 6, 2021

Spectrum submitted the New Drug Application (NDA) for Poziotinib.

Mar 11, 2021

FDA Grants Fast Track Designation (FTD) to Spectrum for Poziotinib.

Dec 19, 2018

Spectrum announced that based on a subset of data from MD Anderson's ongoing Phase 2 study, FDA did not grant Breakthrough Therapy Designation (BTD) to Poziotinib for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have EGFR exon 20 mutations.

Spectrum's BTD application included data from 30 patients from MD Anderson's Phase 2 study who had failed platinum-based chemotherapy.

Spectrum reported that the MDAnderson data demonstrated a confirmed objective response rate of 40% and median duration of response of 6.6 months.

Spectrum stated the safety profile in this subset was consistent with historical data published on poziotinib and other tyrosine kinase inhibitors. The historical objective response rates for mutation specific NSCLC patients range between 0% and 8% with tyrosine kinase inhibitors and for non-mutation specific NSCLC patients range between 0.8% and 22.9% with other treatments.

2018 Spectrum submits Poziotinib application for Breakthrough Therapy Designation (BTD) to FDA based on data reported on patients treated by John V. Heymach and medical staff at the MD Anderson Cancer Center.

Sep 24, 2018

Spectrum Announced the release of updated Poziotinib data From MD Anderson's Phase 2 Study in Non-Small Cell Lung Cancer Patients.

May 3, 2018

Patent Licensing Agreement announced by and between The University of Texas MD Anderson Cancer Center (MDACC) and Spectrum Pharmaceuticals to cover discoveries by John V. Heymach and Heymach's research staff at MDACC in the future.

The filed patents, if granted, are expected to extend the intellectual property protection to 2037.

Oct 27, 2017

Spectrum highlights Poziotinib Data in Non-Small-Cell Lung Cancer (NSCLC) from research results reported by John V. Heymach and The University of Texas MD Anderson Cancer Center.

At the 18th IASLC World Conference on Lung Cancer in Japan, Spectrum presented data reported by Heymach and the MD Anderson Cancer Center research team illustrating that Poziotinib demonstrated evidence of significant antitumor activity in NSCLC patients with EGFR exon 20 insertion mutations, with interim data showing an Objective Response Rate of 73%.

Evidence of central nervous system (CNS) activity in a patient with CNS metastasis and another with leptomeningeal disease (LMD).

March 17, 2017

First Poziotinib clinical trial patient enrolled by John V. Heymach into the Investigator Study Protocol 2016–0783.

Feb. 23, 2017

John V. Heymach initiated the Investigator IND as the Study Sponsor to of the clinical research, Protocol 2016–0783, “A Phase II Study of Poziotinib in EGFR or HER2 Mutant Advanced Solid Tumors” in collaboration with Spectrum and National Cancer Institute (NCI).

From Wikipedia’s article on Spectrum Pharmaceuticals, shared under CC BY-SA 4.0.7

Former names

  • NEOTHERAPEUTICS INCNov 12, 1996 to Dec 11, 20026

Timeline

  1. Aug 1, 20238-K Completed an acquisition or sale; Listing notice or transfer; Change to shareholders' rights56
  2. Jul 27, 20238-K Shareholder vote; Other events57
  3. May 17, 20238-K Other events58
  4. May 9, 20238-K Results of operations59
  5. May 1, 20238-K Executive or director change60
  6. Apr 25, 20238-K Entered a material agreement; Other events61
  7. Apr 4, 20238-K Bylaws or fiscal year changed62
  8. Apr 3, 20238-K Executive or director change63
  9. Mar 22, 20238-K Results of operations64
  10. Mar 10, 20238-K Regulation FD disclosure65
  11. Feb 9, 20238-K Other events66
  12. Jan 31, 20238-K Results of operations67
  13. Feb 14, 2022New chief executive Thomas J. Riga becomes CEO17
  14. Jan 19, 2018New chief executive Joseph W. Turgeon becomes CEO18
  15. Jan 4, 2006New chief executive Rajesh C. Shrotriya Md. becomes CEO19
  16. Nov 18, 2002Founded Spectrum Pharmaceuticals is founded4

Calendar

When it reported results

  1. May 9, 2023Reported quarterly or annual results59
  2. Mar 22, 2023Reported quarterly or annual results64
  3. Jan 31, 2023Reported quarterly or annual results67
  4. Nov 10, 2022Reported quarterly or annual results68
  5. Aug 11, 2022Reported quarterly or annual results69
  6. May 12, 2022Reported quarterly or annual results70
  7. Nov 10, 2021Reported quarterly or annual results71

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

176 filings to the SEC since October 2021: 3 annual reports, 5 quarterly reports, 33 major events, 48 insider forms, 12 large holders, 75 other. The latest 20:

  1. Nov 9, 202315-12G EDGAR
  2. Sep 27, 2023EFFECT EDGAR
  3. Sep 27, 2023EFFECT EDGAR
  4. Sep 27, 2023EFFECT EDGAR
  5. Sep 27, 2023EFFECT EDGAR
  6. Sep 27, 2023EFFECT EDGAR
  7. Sep 27, 2023EFFECT EDGAR
  8. Sep 27, 2023EFFECT EDGAR
  9. Sep 27, 2023EFFECT EDGAR
  10. Sep 27, 2023EFFECT EDGAR
  11. Sep 27, 2023EFFECT EDGAR
  12. Sep 27, 2023EFFECT EDGAR
  13. Sep 27, 2023EFFECT EDGAR
  14. Sep 27, 2023EFFECT EDGAR
  15. Sep 27, 2023EFFECT EDGAR
  16. Sep 27, 2023EFFECT EDGAR
  17. Sep 27, 2023EFFECT EDGAR
  18. Sep 27, 2023EFFECT EDGAR
  19. Sep 27, 2023EFFECT EDGAR
  20. Sep 27, 2023EFFECT EDGAR

The 176 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

40 open-market trades by officers, directors and large owners since October 2021: 1 buys and 39 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
May 26, 2023Brennan NoraSee RemarksSale32,387$1.10$35.6KForm 4
Mar 15, 2023McGahan Keith MSee RemarksSale27,197$0.80$21.8KForm 4
Mar 15, 2023Riga Thomas JSee RemarksSale31,381$0.80$25.1KForm 4
Mar 14, 2023McGahan Keith MSee RemarksSale15,733$0.82$12.9KForm 4
Mar 14, 2023Riga Thomas JSee RemarksSale18,153$0.82$14.9KForm 4
Feb 23, 2023McGahan Keith MSee RemarksSale18,385$0.77$14.2KForm 4
Feb 22, 2023McGahan Keith MSee RemarksSale11,990$0.76$9.1KForm 4
Feb 22, 2023Riga Thomas JSee RemarksSale37,009$0.77$28.4KForm 4
Jan 31, 2023McGahan Keith MSee RemarksSale41,014$0.62$25.4KForm 4
Jan 31, 2023Riga Thomas JSee RemarksSale107,424$0.66$70.9KForm 4
Jan 30, 2023McGahan Keith MSee RemarksSale26,138$0.54$14.1KForm 4
Jan 30, 2023Riga Thomas JSee RemarksSale69,389$0.54$37.5KForm 4
Jan 3, 2023Riga Thomas JSee RemarksSale23,929$0.38$9.1KForm 4
Nov 30, 2022Vacirca Jeff LDirectorBuy50,000$0.45$22.5KForm 4
Jun 23, 2022LEBEL FRANCOISChief Medical OfficerSale6,667$0.84$5.6KForm 4
Jun 22, 2022LEBEL FRANCOISChief Medical OfficerSale6,096$0.81$4.9KForm 4
Jun 21, 2022Brennan NoraSee RemarksSale3,569$0.79$2.8KForm 4
Jun 21, 2022Fischer Seth H. Z.DirectorSale5,711$0.79$4.5KForm 4
Jun 21, 2022Vyas DolatraiSale4,283$0.79$3.4KForm 4
Jun 21, 2022Ashton WilliamDirectorSale4,283$0.79$3.4KForm 4

All 40 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How Spectrum Pharmaceuticals is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARSPECTRUM PHARMACEUTICALS INC2
  • CIK0000831547
  • Employer ID (EIN)93-09791872
  • Filer statusNon-accelerated filer<br>smaller reporting company2
  • Incorporated inDelaware2
  • Fiscal year endsDecember 312
  • Industry code (SIC)2834 Pharmaceutical Preparations2
  • Business address11500 S. Eastern Ave., Suite 240, Henderson, NV 890522
  • Phone702-835-63002
  • Shares outstanding205,261,531 as of May 9, 202314
  • Public float$115.4M as of Jun 30, 202278
  • On EDGAR sinceNov 12, 19962
  • Filings1,772 in all: 4 (578), 8-K (373), SC 13G/A (90), 10-Q (74), SC 13G (61), CT ORDER (40), 424B3 (38), 3 (36)2
    All 66 form types

    CORRESP (30), EFFECT (30), S-3 (29), UPLOAD (28), DEF 14A (27), 424B5 (25), POS AM (25), 10-K (24), DEFA14A (23), SC 13D/A (22), S-3/A (18), 11-K (17), 5 (17), SC TO-T/A (17), S-8 (16), S-8 POS (12), 10-K/A (10), PRE 14A (10), 8-K/A (9), 4/A (8), ARS (7), 10QSB (6), REGDEX (6), SC 13D (6), 144 (5), 424B2 (5), NT 10-K (4), 425 (3), NT 10-Q (3), S-1/A (3), 10-Q/A (2), 10KSB (2), 10KSB/A (2), 10QSB/A (2), 15-12G (2), D (2), S-1 (2), SB-2/A (2), SC TO-I/A (2), 10-K405 (1), 11-K/A (1), 25-NSE (1), 424B4 (1), 8-A12B (1), 8-A12B/A (1), 8-A12G (1), 8-B12G (1), DEFM14A (1), DEFS14A (1), NT 10-K/A (1), NT 11-K (1), PRES14A (1), RW (1), S-3ASR (1), S-3MEF (1), SC TO-C (1), SC TO-I (1), SC TO-T (1)

  • Latest filingsAnnual report (10-K) Mar 31, 2023
    Quarterly report (10-Q) May 11, 2023
    Proxy statement (DEF 14A) Apr 27, 2022
    Latest 8-K (8-K) Aug 1, 2023

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
    SEC EDGAROther events
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
    SEC EDGAROther events
  67. 67
  68. 68
  69. 69
  70. 70
  71. 71
  72. 72
  73. 73
  74. 74
  75. 75
  76. 76
  77. 77
  78. 78